Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1859-1867

  Skiada, A ^a   Pagano, L ^b   Groll, A ^c   Zimmerli, S ^d   Dupont, B ^e   Lagrou, K ^f   Lass Florl, C ^g   Bouza, E ^h   Klimko, N ⁱ   Gaustad, P ^j   Richardson, M ^k,l   Hamal, P ^m   Akova, M ⁿ   Meis, J F ^o   Rodriguez Tudela, J L ^p   Roilides, E ^q   Mitrousia Ziouva, A ^a   Petrikkos, G ^r  

^a UNIVERSITY OF ATHENS   (Greece)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k WYTHENSHAWE HOSPITAL   (United Kingdom)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m PALACKÝ UNIVERSITY   (Czech Republic)

ⁿ HACETTEPE UNIVERSITY   (Turkey)

^o CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^p INSTITUTO DE SALUD CARLOS III   (Spain)

^q ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^r UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

Epidemiology; Europe; Mucormycosis; Treatment; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ABSIDIA; ADULT; AGED; ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; EUROPE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MUCOR; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS; ZYGOMYCOSIS;

ABSIDIA; MUCOR; RHIZOPUS;

EID: 79955524549     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03456.x     Document Type: Article

References (32)

1. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-1401.
2. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-associated infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010; 50: 1091-1100.
3. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-associated infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
4. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
5. Chayakulkeeree M, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-229.
6. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK Jr, Walsh TJ. Zygomycosis in neonates: an uncommon, but life-threatening infection. Am J Perinatol 2009; 26: 565-573.
7. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952.
8. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862-870.
9. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
10. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138-1147.
11. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (suppl 1): 31-47.
12. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61 (suppl 1): 35-39.
13. Gleissner B, Schilling A, Anagnostopolous I et al. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004; 45: 1351-1360.
14. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-1751.
15. Bialek R, Konrad F, Kern J et al. PCR-based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005; 58: 1180-1184.
16. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus group. Clin Infect Dis 2008; 46: 1813-1821.
17. Ruping MJGT, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.
18. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect 2009; 15 (Suppl 5): 55-69.
19. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological manlignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto). Br J Haematol 1997; 99: 331-336.
20. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005; 18: 556-569.
21. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214.
22. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis: report of four cases and review. Rev Infect Dis 1989; 5: 741-754.
23. Dannaoui E, Schwarz P, Slany M et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010; 48: 2043-2046.
24. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-429.
25. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199: 1399-1406.
26. Sun QN, Fothergill AW, McCarthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582.
27. Almyroudis NG, Sutton DA, Fothergill AW et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-2590.
28. Dannaoui E, Meletiadis J, Mouton JW, Meis JFGM, Verweij PE, the Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
29. Arikan S, Sancak B, Alp S et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008; 46: 567-573.
30. Dannaoui E, Meis JFGM, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-3650.
31. Schlemmer F, Lagrange-Xelot M, Lacroix C et al. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 42: 551-552.
32. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008; 14: 189-193.